Hikma Pharmaceuticals Plc Notice of Results (1641P)
February 07 2023 - 4:36AM
UK Regulatory
TIDMHIK
RNS Number : 1641P
Hikma Pharmaceuticals Plc
07 February 2023
Notice of preliminary results
London, 7 February 2023 - Hikma Pharmaceuticals PLC (Hikma,
Group), will announce its preliminary financial results for the
year ended 31 December 2022 on Thursday 23 February 2023.
A recording of the 2022 Preliminary Results presentation and
slide deck will be available on the Group's website at
www.hikma.com from 7:00am GMT. Hikma will also hold a Q&A call
for analysts at 11:00am GMT, and a recording will be made available
on the Company's website.
To join the call please, please register your attendance in
advance by clicking here .
For further information please contact Tiina Lugmayer -
tlugmayer@hikma.com .
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760/ +44 (0)7776
Affairs 477050
Guy Featherstone +44 (0)20 3892 4389/ +44 (0)7795
Associate Director, Investor Relations 896738
Layan Kalisse +44 (0)20 7399 2788/ +44 (0)7970
Senior Associate, Investor Relations 709912
Teneo (Press):
Charles Armitstead / Camilla Cunningham +44 (0)7703 330 269/ +44 (0)7464 982426
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and
BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,600 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFZGGZLNDGFZG
(END) Dow Jones Newswires
February 07, 2023 04:36 ET (09:36 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024